Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20474031 | 0.84 | CCNA2 (0.35) | KDM4EPKMCNR2TLR9TLR8 | |
| SCHEMBL21824368 | 0.80 | PKM (0.31) | PKMPOLB | |
| SCHEMBL20474023 | 0.80 | PKM (0.34) | KDM4EPKMCNR2TLR9TLR8 | |
| SCHEMBL29905537 | 0.76 | POLB (0.33) | PKMRIPK1POLB | |
| SCHEMBL21824349 | 0.74 | POLB (0.36) | PKMCNR2POLB | |
| SCHEMBL21824332 | 0.74 | POLB (0.36) | PKMCNR2TLR9TLR8TLR7 | |
| SCHEMBL21824343 | 0.69 | POLB (0.35) | PKMCNR2RIPK1POLB | |
| SCHEMBL20474033 | 0.64 | TLR9 (0.42) | PKMTLR9TLR8TLR7RIPK1 | |
| SCHEMBL29905684 | 0.63 | KDM4E (0.43) | KDM4EPKMCNR2RIPK1POLB | |
| SCHEMBL174681 | 0.62 | SMN1; SMN2 (0.44) | PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200109132-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2020-04-09 | — | — | US | disclosed |
| US-20180237421-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2018-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109132-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINE1 | KDM4E 1691/4885MAP3K12 328/4885PKM 299/4885 |
| US-20180237421-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINE1 | KDM4E 1691/4885MAP3K12 328/4885PKM 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.